Association between adherence to anti-diabetic therapy and adverse maternal and perinatal outcomes in diabetes in pregnancy

Doreen Macherera Mukona*, Stephen Peter Munjanja#, Mathilda Zvinavashe and Babil Stray-Pederson

* Department of Nursing Science, University of Zimbabwe College of Health Sciences, Harare, Zimbabwe
# Department of Obstetrics and Gynecology, University of Zimbabwe College of Health Sciences, Harare, Zimbabwe
† Institute of Clinical Medicine, Oslo University and Division Women and Children, Oslo, Norway
*Corresponding author, email: dmacherera@yahoo.co.uk

Objectives: To analyse the association between adherence to anti-diabetic therapy (diet, physical activity and medications) and perinatal outcomes.

Methods: A cohort design was used. Participants were 157 pregnant women with diabetes, and the setting was Mbuya Nehanda and Chitungwiza Maternity Hospitals, Harare, Zimbabwe.

Results: Main outcome measures were maternal and perinatal outcomes. Mean adherence to anti-diabetic therapy was 66.7%. Perinatal outcomes observed were hypertensive disorders (34.5%), Caesarean delivery (45.9%), maternal diabetic ketoacidosis (5.1%), maternal hypoglycaemia (15.9%), and candidiasis (19.7%). Neonatal outcomes were perinatal mortality (15.9%), low Apgar score at 1 minute (26.8%), low Apgar score at 5 minutes (24.8%), macrosomia (33.8%), neonatal hypoglycaemia (15.3%), and neonatal hyperbilirubinemia (7.6%). There were significant associations between adherence and Caesarean delivery (RR 1.9, 95% CI 1.28 to 2.81, p = 0.0014), candidiasis (RR 3.95, 95% CI 1.65 to 9.47, p = 0.002), low Apgar score at 1 minute (RR 2.15, 95% CI 1.16 to 3.98, p = 0.0014), candidiasis (RR 3.95, 95% CI 1.65 to 9.47, p = 0.002), low Apgar score at 5 minutes (RR 1.95, 95% CI 1.03 to 3.69, p = 0.039), and perinatal mortality (RR 3.08, 95% CI 1.11 to 8.52, p = 0.018).

Conclusions: Adherence to anti-diabetic therapy was sub-optimal and was associated with some adverse perinatal outcomes. Promotion of adherence, through routine individualised counselling, monitoring and assessment, is vital to minimise adverse outcomes.

Keywords: anti-diabetic therapy, diabetes, maternal outcomes, perinatal outcomes, pregnancy

Introduction
Diabetes mellitus is a non-communicable disease which is a predominant cause of mortality in Africa. Its global prevalence has risen from 4.7% in 1980 to 8.5% in the adult population. The prevalence of diabetes in Zimbabwe is 5.7%. GDM is glucose intolerance diagnosed during pregnancy after the 24th week of gestation while type I and II diabetes in pregnancy are overt diabetes in previously diagnosed women. The prevalence of gestational type I and type II diabetes is included in the prevalence of diabetes mellitus.

The prevalence of GDM varies between 1% and 14% in all pregnancies depending on the genetic characteristics, environment of the population under study, screening and diagnostic methods employed and prevalence of type II diabetes mellitus. Diabetes in pregnancy increases the risk for various maternal and foetal complications such as pre-eclampsia, postpartum haemorrhage, infection, birth asphyxia, stillbirth and large for gestational age (LGA) infants. High rates of Caesarean delivery then result in macrosomia due to such reasons as cephalo-pelvic disproportion and foetal distress. The Hypoglycaemia and Adverse Pregnancy Outcomes (HAPO) cohort study demonstrated strong evidence of a continuous rather than threshold relationship of pregnancy outcomes with rising hyperglycaemia. Women with well-controlled blood glucose levels can give birth to healthy neonates.

Adherence in pregnant women with diabetes is compromised by overload of advice from different healthcare professionals, self-monitoring of blood glucose (SMBG) and strict dietary manipulation. Physiological demands of pregnancy such as nausea and vomiting compromise adherence to therapy. The main purpose of the study was to develop an adherence promotion framework for women with diabetes in pregnancy to improve adherence and perinatal outcomes. This article focuses on the association between non-adherence and perinatal outcomes.

Methods
This study was conducted at three central hospitals in Zimbabwe with a cohort of 157 pregnant women with diabetes in pregnancy. Consecutive sampling was used. Ethical approval was granted by the respective ethical review boards. All participants gave informed consent. Included in the study were pregnant women aged 18–45 years with diabetes in pregnancy. Excluded from the study were women who had not undergone adherence counselling, the very ill, the institutionalized and those who had previously participated in either the pilot or the main study. Data collection was done from September 2015 to January 2017 through an interviewer-administered questionnaire. The questionnaire had sections on demographics, past and current health history, adherence to diet, physical activity and medications and perinatal outcomes. Adherence level of at least 80%, measured by self-reports, was classified as good adherence while levels below 80% were poor. Participants were followed up from 20–24 weeks’ gestation up to 6 weeks post-delivery. Level of adherence was measured after recruitment and respondents were classified as either having good adherence or poor adherence. They were then followed up till 6 weeks after delivery for monitoring of perinatal outcomes. Data were analysed using the statistical package for Social Sciences (SPSS®) version 20 (IBM Corp, Armonk, NY, USA) and STATA (StataCorp LLC, College Station, TX, USA).
Station, TX, USA). Descriptive statistics were used to analyse demographics, adherence levels and perinatal outcomes. Generalised linear regression modelling was used to analyse associations between adherence and perinatal outcomes and was reported as risk ratios.

Results

Demographic variables
Table 1 presents demographic variables. Forty (25.5%) participants had type I diabetes mellitus, 69 (43.9%) had type II while 48 (30.6%) had GDM. Fifty (31.8%) participants were aged between 30 and 34, 130 (82.8%) were married 113 (72.0%) had attained the ordinary level of education while 91 (58%) were unemployed.

Adherence to anti-diabetic therapy
Table 2 presents adherence to anti-diabetic therapy ranges. Twenty-six (16.6%) scored below 50%, 12 (7.6%) scored from 50–59%, 19 (12.1%) scored from 60–69%, 42 (26.8%) scored from 70–79%, 56 (35.6%) scored from 80–89% while 2 (1.3%) scored 90% and above. Fifty-eight (36.9%) scored 80% and above.

Perinatal outcomes
Table 3 presents perinatal outcomes. Fifty-four (34.4%) had hypertensive disorders while 72 (45.9%) had Caesarean delivery. Fifty-three (33.8%) had macrosomia, 42 (26.8%) had low Apgar score at 1 minute and 39 (24.8%) had low Apgar score at 5 minutes.

Table 4 presents associations between level of adherence and perinatal outcomes. There were significant associations with Caesarean delivery, vaginitis/candidiasis, low Apgar score at 1 minute and at 5 minutes and perinatal mortality.

Discussion
The pregnancy state in diabetes requires even stricter adherence to therapy because of the detrimental effects of hyperglycaemia on both the mother and the foetus. In terms of type of diabetes,
30.6% participants had GDM, 43.9% had pre-gestational type II diabetes while 25.5% had pre-gestational type I diabetes. This translates to 69.4% pre-gestational diabetes. Many studies conducted have reported much higher percentages of GDM in diabetes in pregnancy.17 The lower proportion of GDM in this study could be a reflection of inadequate screening for GDM in the setting due to lack of resources. In high-income countries GDM screening is an established part of antenatal care with specific procedures clearly defined in national guidelines while screening and management of GDM often is not part of routine care in the majority of low-resource settings.12 Guidelines are often absent in low-resource settings where, until now, GDM has received less attention than other causes of perinatal morbidity and mortality.12

The majority (82.8%) of participants were married. This presents an opportunity for male engagement in the care of women with diabetes in pregnancy. Spouses may provide social support to affirm healthy behaviours and social control to modify health behaviours in their partner’s diabetes management.13

This is even more relevant in this study where 58% were unemployed, meaning they could have depended on their husbands for support. In terms of education 88% had attained at least an ordinary level of education. Education is an important factor that has an influence on an individual’s attitude and outlook on various aspects of life.14 This presents an opportunity for effective health education of patients as they are able to internalise information given. The patient should know the basic principles regarding diet, maintenance of body weight, resting, and prevention of hypoglycaemia or deregulation of blood sugar. Optimum glucose control is vital in pregnancy and the prevention of hypoglycaemia or deregulation of blood.

Adherence to anti-diabetic therapy

Adherence to anti-diabetic therapy in this study referred to adherence to diet, medications and physical activity. Though measured separately, a composite score of overall adherence to therapy was calculated. Mean adherence to anti-diabetic therapy was 68.79%. This was low relative to the 80% adherence required for effective glycaemic control in diabetes. Fifty-eight (36.9%) participants scored above the recommended 80% or higher level of adherence. The majority of research on diabetes in pregnancy highlights its epidemiological, pathological and biological aspects with few authors researching the social and behavioural effects of the diagnosis from the viewpoint of the women affected.17 Adherence to therapy is one such social behavioural effect of diabetes in pregnancy. Such studies have been done in non-pregnant diabetic populations and similar rates of suboptimal adherence have been reported.18 19 Non-adherence in diabetes in pregnancy is a very significant problem because diabetes affects pregnant women more than the non-pregnant population due to the presence of more than the usual pregnancy discomforts. Glycaemic control in PGDM is complicated by the presence of physiological pregnancy changes while the need to learn about diabetes and management in a short space of time in GDM is a major challenge. Strict adherence to healthy lifestyle habits must be advocated in health policies worldwide to control diabetes mellitus, particularly in developing countries like Zimbabwe where access to health care and quality of health care are huge problems.

Perinatal outcomes

The most common maternal perinatal outcomes reported in the study were Caesarean delivery (45.9%) and PIH (34.4%). Caesarean delivery is common in diabetic pregnant mothers due to macrosomia.8 The incidence of macrosomia in this study was 33.8%. The incidence of Caesarean delivery in this study is lower than incidences reported elsewhere in the literature. Rates of Caesarean delivery as high as 92.8%20 in India, and 89%21 in Nigeria have been reported in the literature. Some rates of Caesarean delivery reported were 74.3%22 in Nigeria and 56% and 39.8% in GDM and in insulin-dependent groups respectively23 in South Africa. González-Quintero et al. (2007) reported a Caesarean delivery rate of 48.5% in the USA.24 Studies have also demonstrated an increased risk of Caesarean delivery in diabetes in pregnancy.25 Vaginal delivery of such babies has been associated with shoulder dystocia, birth asphyxia and birth injury, thus the high rates of Caesarean delivery. Other studies have reported lower rates of Caesarean delivery than the one reported in this study. Ozumba et al. (2004) revealed an overall Caesarean section rate of 36% among diabetics in a study conducted in Nigeria.8 Previous Caesarean section and cephalo-pelvic disproportion were the common indications for Caesarean delivery. Another study conducted in Taiwan reported a rate of Caesarean delivery of 31.6%.6 Hypertensive disorders in pregnancy are also indications for Caesarean delivery and in this study 34.4% participants had hypertensive disorders.

Hypertensive disorders of pregnancy are common in diabetes in pregnancy where they lead to higher maternal and foetal morbidity and also increase the risk for future cardiovascular events.26 The incidence of hypertensive disorders in this study was 34.4%. Poor adherence in this study that consequently influences glycaemic control, which is a risk factor for hypertension,27 could explain the high incidence of hypertensive disorders. This is lower than the incidence of hypertension complicating pregnancy of 40% to 45% in women with PGDM as reported by Cundy et al. (2002).28 Huddie (2005) reported an incidence of 13.1% of hypertension in an audit of outcome of diabetic pregnancy conducted in South Africa.29 Billionet et al. (2017) reported an increased risk of pre-eclampsia/eclampsia in PGDM mothers compared with GDM mothers in a study conducted in France.29

The rate of macrosomia in this study was 33.8%. Macrosomia is common in diabetes in pregnancy due to a rapid growth rate of the foetus as a result of high glucose levels crossing the placenta by facilitated diffusion during pregnancy.30 This rate is comparable to rates reported in other studies. González-Quintero et al. (2007) reported rates of 15.7% and 19.8% for macrosomia and LGA respectively in the United States. Wang et al. (2013)31 reported a rate of macrosomia of 17%. Other studies have reported even higher rates of macrosomia. Murphy et al. (2011) reported a rate of macrosomia of 37.6% in type II diabetics and 52.9% in type I diabetics,32 while John et al. (2015) reported a rate of 49%.33 Opara et al. (2010) reported a rate of 61.7%. Billionet et al. (2017)34 and Wahabi et al. (2013)35 reported an increased risk of macrosomia in GDM. A high incidence of some complications of diabetes in pregnancy such as macrosomia may indicate poorer care for women with diabetes in pregnancy in low-resource settings.36
The rate of neonatal hypoglycaemia in this study was 15.3%. Hypoglycaemia is one of the most frequent complications of diabetes in the baby, and the incidence ranges from 30% to 50% depending on maternal glucose control during pregnancy, duration of labour, blood glucose level at the time of delivery and whether there was early or late feeding. This rate is higher than 9.3% reported by González-Quintero et al. (2007) in the USA. It is much lower than 63.8% reported by Opara et al. (2010) in Nigeria.

The rate of perinatal mortality rate in the study was 15.9%. Perinatal mortality rate (PMR) is an important perinatal health indicator and is always higher in diabetic pregnancies than in the background PMR. It is driven by congenital malformations of the neonate. This rate could be comparable to the 124 per 1,000, while a British study in 1,706 women with type 1 diabetes mellitus reported an increased risk of prematurity in diabetes in pregnancy. The rate of prematurity in this study was 5.1%. This rate is lower than the rates reported by Murphy et al. (201) of 17.5% and 37.1% in type II and type I diabetes respectively. The high rate observed in this current study could be attributed to the rising incidence of type II diabetes mellitus coupled with improved screening for GDM compared with almost three decades ago. High perinatal mortality rate might reflect poorer glycaemic control and poorer management of diabetes in pregnancy in the setting. Yang et al. (2006) reported a perinatal mortality rate of 11.5 per 1,000, compared with 4.8 per 1,000 that was estimated in 62,079 normal pregnancies in Nova Scotia. A French study on 289 pregnancies with type-1 diabetes mellitus reported an incidence of 66 per 1,000. While a British study in 1,706 women with type I diabetes mellitus reported an incidence of intrauterine deaths of 25.8 per 1,000 and an incidence of perinatal mortality of 31.7 per 1,000. High PNM rates could be indicative of poorer perinatal outcomes, probably due to poor glycaemic control and challenges in the management of diabetes in pregnancy in the setting. Lower rates have also been reported in the literature. Huddle (2005) reported a PNM of 4.5% in infants born to diabetic mothers. John et al. (2015) reported 11 perinatal deaths (perinatal mortality rate 90 per 1,000 deliveries) in women with diabetes in pregnancy. Other studies have reported an increased risk of perinatal mortality in PGDM compared with GDM. Comparison of PGDM and GDM in this setting might be difficult to under-diagnosis of GDM resulting in small numbers compared with GDM, late booking of pregnancies and limited access to tests such as HbA1C to distinguish between true GDM and undiagnosed PGDM. In Saudi Arabia Wahabi et al. (2017) reported an increased risk of stillbirth (OR 3.66; 95% CI 1.98–6.72) in neonates of mothers with pre-GDM while González-Quintero et al. (2007) reported a rate of still births in GDM of 0.3%.

The rate of prematurity in this study was 5.1%. This rate is lower than the rates reported by Murphy et al. (201) of 17.5% and 37.1% in type II and type I diabetes respectively. The high rate reported by Murphy could reflect the preference for premature delivery in the presence of significant complications in order to save the mother’s and the baby’s health. Prematurity is a risk factor for other complications such as intrauterine growth restriction, low birth weight, respiratory distress syndrome, hypoglycaemia, hypocalcaemia, polycythaemia, intrauterine death, hyperbilirubinemia, several types of malformations, hypertrophic cardiomyopathy and asphyxia. Some studies have reported no differences in incidence of prematurity in women with GDM and those without while others have reported an increased risk of prematurity in diabetes in pregnancy.

Other neonatal outcomes observed in the study were low Apgar score at 1 minute (26.8%), low Apgar score at 5 minutes (24.8%) and low birth weight (7%). Rates of low Apgar score could have been due to macrosomia and prematurity in the study. Hyperbilirubinemia may be seen in the first 24 to 72 hours of life. The presence of hyperglycaemia and hyperinsulinemia in diabetes in pregnancy result in impairment of placental blood flow and transplacental exchanges resulting in a state of chronic relative hypoxaemia. The rate of neonatal hyperbilirubinemia in this study was 7.6%. González et al. (2007) reported a rate of 10.1% in the USA while Opara et al. (2010) reported a rate of 57.4% in Nigeria. Hyperbilirubinemia is common even in neonates born to non-diabetic mothers. In diabetes in pregnancy it is worsened by hyperglycaemia and hyperinsulinemia.

Association between adherence to anti-diabetic therapy and adverse maternal and perinatal outcomes in diabetes in pregnancy

Participants with poor adherence (< 80%) were 3.95 times more likely to have vaginal infections (RR 3.95; 95% CI 1.65–9.47, p = 0.002) compared with women who had high adherence (≥ 80%). Diabetes and yeast infection can co-occur during pregnancy. Uncontrolled blood sugar in diabetes in pregnancy is a major risk factor for candidiasis.

The associations between adherence and other maternal perinatal outcomes were not significant. The relative risks for other maternal outcomes were hypertensive disorders (RR 1.28, 95% CI 0.8–2.03, p < 0.305), maternal DKA (RR 1.76, 95% CI 0.38–4.59, p < 0.473), maternal hypoglycaemia (RR 1.50, 95% CI 0.68–3.34, p < 0.312) and preterm birth (RR 1.76, 95% CI 0.38–8.23, p < 0.473). The Hypoglycaemia and Adverse Pregnancy Outcomes (HAPO) cohort study demonstrated strong evidence of a continuous rather than threshold relationship of pregnancy outcomes with rising hyperglycaemia.
The independent associations between adherence and hypertensive disorders, maternal hypoglycaemia, maternal DKA and preterm birth were not significant. However, larger studies have shown significant associations between maternal glycaemia, represented by level of adherence in this study, and these perinatal outcomes. The differences from the findings of this study could be due to differences in sample sizes and the subjective methods of measuring adherence used. Other studies used objective measures, namely fasting plasma glucose levels and post-prandial glucose levels.

Participants with poor adherence (< 80%) were 2.15 times more likely to have a baby with low Apgar at one minute (RR 2.15, 95% CI 1.16–3.98, p = 0.015) and 1.15 times more likely to have a baby with low Apgar score at 5 minutes (RR 1.95, 95% CI 1.03–3.69, i = 0.039) compared with women who had high adherence (≥ 80%). A low Apgar score is one of the complications of macrosomia.

Participants with poor adherence (< 80%) were 3.08 times more likely to have perinatal mortality (RR 3.08, 95% CI 1.11–8.52, p = 0.018) compared with women who had good or very good adherence (≥ 80%). Though major contributors are intrauterine growth restriction, pre-eclampsia, foetal hypoxia and congenital malformations, more than half of stillbirths are unexplained. However, the majority are characterised by maternal hyperglycaemia. This was reflected in the present study where mean adherence to anti-diabetic therapy was suboptimal, which might have resulted in maternal hyperglycaemia.

There was a non-significant association between low adherence and having a macrosomic baby (RR 0.89, 95% CI 0.57–1.40, p < 0.619). This is in disagreement with findings of the HAPO study and Farrar et al., which revealed a significant association between maternal hyperglycaemia and macrosomia. Many other studies have reported an increased risk of macrosomia with rising glycaemia. The differences in findings could be a result of different sample sizes. Farrar et al. revealed that the odds ratios for large for gestational age per 1 mmol/l increase of fasting and two-hour post-load glucose concentrations (after a 75 g OGTT) were 2.15 (95% confidence interval 1.60–2.91) and 1.20 (1.13–1.28), respectively.

There was an unusual association between low adherence and neonatal hypoglycaemia (RR 0.14, 95% CI 0.19–0.86, p > 0.019). The finding insinuates that low adherence is protective of hypoglycaemia. This finding is biologically implausible and could be a result of small numbers. The sample size for the quantitative phase of the study was 157. A number of studies have demonstrated significant increases in risk of neonatal hypoglycaemia with rising maternal glycaemia. Neonatal hypoglycaemia occurs in approximately 8–30% of infants of diabetic mothers. Findings of this study underscore the importance of strict glycaemic control in pregnancy through adherence to anti-diabetic therapy in a resource-limited setting.

Disclosure statement – No potential conflict of interest was reported by the authors.

Limitations of the study – Data were collected by self-reports, which could have overestimated adherence to anti-diabetic therapy. Though objective measures such as drug levels for adherence to medication and the doubly labelled water technique for physical activity are the best, they are very expensive and not feasible in a resource-limited setting.

References
1. World Health Organization. Global report on diabetes. Geneva: World Health Organization; 2016. Report No.: 9241565525X.
2. Gumbie MP, Gowda U, Mangwiro JC, et al. Prevalence of diabetes in Zimbabwe: a systematic review with meta-analysis. Int J Public Health. 2015;60(1):1–11.
3. Keshavarz M, Cheung NW, Babae GR, et al. Gestational diabetes in Iran: incidence, risk factors and pregnancy outcomes. Diabetes research and clinical practice. 2005;69(3): 279–86. https://doi.org/10.1016/j.diabres.2005.01.011
4. Borboonhirunsan D, Waiyankorn R. Emergency cesarean section rate between women with gestational diabetes and normal pregnant women. Taiwanese Journal of Obstetrics and Gynecology. 2016;55(1):64–67. https://doi.org/10.1016/j.tjog.2015.08.024
5. Crowther CA, Hiller JE, Moss JR, et al. Effect of treatment of gestational diabetes mellitus on pregnancy outcomes. Australian Carbohydrate Intolerance Study in Pregnant Women (ACHOIS) Trial Group. The New England J Med. 2005;352(24):2477–86. https://doi.org/10.1056/NEJMoa042973
6. Gasim T. Gestational diabetes mellitus: maternal and perinatal outcomes in 220 saudi women. Oman Med J. 2012;27(2):140–4. https://doi.org/10.5001/omj.2012.29
7. White K, Terry D, Troup C, et al. Predicting the consumption of foods low in saturated fats among people diagnosed with Type 2 diabetes and cardiovascular disease. The role of planning in the theory of planned behaviour. Appetite. 2010;55(2):348–54. https://doi.org/10.1016/j.appet.2010.07.011
8. Ozumba B, Obi S, Oli J. Diabetes mellitus in pregnancy in an African population. Int J Gynecol Obstet. 2004;84(2):114–119. https://doi.org/10.1016/S0020-7292(03)00210-8
9. Albrecht SS, Kukinka EV, Bansil P, et al. Diabetes trends among delivery hospitalizations in the US, 1994–2004. DiabetesCare. 2010;33(4):768–73. https://doi.org/10.2337/dc09-1801
10. Fong A, Serra A, Herrero T, et al. Pre-gestational versus gestational diabetes: a population based study on clinical and demographic differences. J Diabetes and its Complications. 2014;28(1):29–34. https://doi.org/10.1016/j.jdiacomp.2013.08.009
11. Wahabi H, Fayad A, Esmaeil S, et al. Prevalence and complications of pregestational and gestational diabetes in saudi women: analysis from rijayd mother and baby cohort study (RAHMA). BioMed Res Int. 2017;2017:1–9. doi:10.1155/2017/6878263.
12. Utz B, Kolsteren P, De Brouwere V. Screening for gestational diabetes mellitus: are guidelines from high-income settings applicable to poorer countries? Clin Diabetes. 2015;33(3):152–158. https://doi.org/10.2337/diaclin.33.3.152
13. Khan CM, Stephens MAP, Franks MM, et al. Influences of spousal support and control on diabetes management through physical activity. Health Psychology. 2013;32(7):739–47. https://doi.org/10.1037/a0028609
14. Zimbabwe National Statistics Agency. Nuptiality and fertility thematic report. 2015.
15. Yee L, McGuire J, Taylor S, et al. Factors promoting diabetes self-care among low-income, minority pregnant women. Journal of Perinatology. 2016;36(1):13–24. https://doi.org/10.1038/jp.2015.134
16. Huang J, Liu Y, Zhang Y, et al. Correlation between self-management and knowledge of and attitude to diabetes in type 2 diabetic patients in Changsha. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2013;38(2):176–181.
17. Lawrence JM. Women with diabetes in pregnancy: different perceptions and expectations. Best Practice & Research Clinical Obstetrics & Gynaecology. 2011;25(1):15–24. https://doi.org/10.1016/j.bpobgyn.2010.10.003
18. Mkonka L, Mukona D, Zvinavashe M, et al. Factors related to non-adherence to lifestyle modification in patients with diabetes mellitus type 2 at harare central hospital. IOSR Journal of Nursing and Health Science (IOSR-JNHS). 2016;5(5):77–85.
19. Mumu S, Saleh F, Ara F, et al. Non-adherence to life-style modification and its factors among type 2 diabetic patients. Indian J Public Health. 2014;58(1):40–44. https://doi.org/10.4103/0019-557X.128165
Association between adherence to anti-diabetic therapy and adverse maternal and perinatal outcomes in diabetes in pregnancy

20. Varghese R, Thomas B, Al Hail M, et al. The prevalence, risk factors, maternal and fetal outcomes in gestational diabetes mellitus. Int J Drug Dev Res. 2012;4(3): 356–68.

21. John C, Alegbeleye J, Otoide A. Foeto-maternal outcome of diabetes in a tertiary health facility in Nigeria. Afr J Diabetes Med. 2015;23(2): 13–16.

22. Opara P, Jaja T, Onubogu U. Morbidity and mortality amongst infants of diabetic mothers admitted into a special care baby unit in Port Harcourt, Nigeria. Ital J Pediatrics. 2010;36(77): 1–6.

23. Huddle K. Audit of the outcome of pregnancy in diabetic women in Soweto, South Africa, 1992–2002. S Afr Med J. 2005;95(10):789–94.

24. González-Quintero VH, Istwan NB, Rhea DJ, et al. The impact of glycemic control on neonatal outcome in singleton pregnancies complicated by gestational diabetes. Diabetes care. 2007;30(3):467–70. https://doi.org/10.2337/dc06-1875

25. Wahabi H, Eismael S, Fayed A, et al. Gestational diabetes mellitus: maternal and perinatal outcomes in King Khalid university hospital, Saudi Arabia. J Egypt Public Health Assoc. 2013;88(2): 104–8. https://doi.org/10.1097/EP.J.0b013e31829ca7a3

26. Sullivan S, U mans J, Ratner R. Hypertension complicating diabetic pregnancies: pathophysiology, management, and controversies. J Clin Hypertens. 2011;13(4): 275–84.

27. Thompson D, Berger H, Feig D, et al. Clinical practice guidelines diabetes and pregnancy canadiandiabetes association clinical practice guidelines expert committee. Can J Diabetes 2013;37:5168–583. https://doi.org/10.1016/j.jcjd.2013.01.044

28. Cundy T, S le F, Gam ble G, et al. Hypertensive disorders of pregnancy in women with type 1 and type 2 diabetes. Diabetic Med. 2002;19(6):482–9. https://doi.org/10.1046/j.1464-5491.2002.00729.x

29. Billionnet C, Mitranchez D, Welli A, et al. Gestational diabetes and adverse perinatal outcomes from 716,152 births in France in 2012. Diabetologia. 2017;60(4):636–644. https://doi.org/10.1007/s00125-017-4206-6

30. Schneiderman EH. Gestational diabetes: an overview of a growing health concern for women. J Infusion Nursing. 2010;33(1):48–54. https://doi.org/10.1097/NAN.0b013e3181c6d9f3

31. Wang C, Wei Y, Yang H. Analysis of the effects of gestational diabetes mellitus based on abnormal blood glucose on pregnancy outcomes article in Chinese. Zhonghua Fu Chan Ke Za Zhi. 2013;48(12):899–902.

32. Murphy H, Steel S, Roland J, et al. Obstetric and perinatal outcomes in pregnancies complicated by type 1 and type 2 diabetes: influences of glycaemic control, obesity and social disadvantage. Diabetic Med. 2011;28(9):1060–67. https://doi.org/10.1111/j.1464-5491.2011.03287.x

33. Wang Z, Kanguru L, Hussein J, et al. Incidence of adverse outcomes associated with gestational diabetes mellitus in low- and middle-income countries. Int J Gynecol Obstet. 2013;121(1):14–19.

34. Negrato CA, Mattar R, Gomes MB. Adverse pregnancy outcomes in women with diabetes. Diabetology and Metab Syndrome. 2012;4(1): 1–6.

35. Vitoratos N, Vrachnis N, Valsamakis G, et al. Perinatal mortality in diabetic pregnancy. Ann NY Acad Sci. 2010;1205:94–98. https://doi.org/10.1111/j.1749-6632.2010.05670.x

36. Macintosh M, Fleming K, Bailey J. Perinatal mortality and congenital abnormalities in babies of women with type 1 or type 2 diabetes in England, Wales, and Northern Ireland: population based study. BMJ. 2008;337:177–182.

37. Chrienje M. The effects of established and gestational diabetes on pregnancy outcome at Harare maternity hospital. Cent Afr J Med. 1992;38(5):179–181.

38. Diabetes and Pregnancy Group France. French multicentric survey of outcomes of pregnancy in women with pregestational diabetes. Diabetes Care. 2003;26: 2990–2993.

39. Yang J, Cummings E, O’Connell C, et al. Fetal and neonatal outcomes of diabetic pregnancies. Obstetrics & Gynecology. 2006;108:644–650. https://doi.org/10.1097/01.AOG.0000216888.08263.47

40. Rwegerera GM, Moshomo T, Gaenamong M, et al. Antidiabetic medication adherence and associated factors among patients in Botswana; implications for the future. Alexandria J.Med. 2017;1:1–5. doi:10.1016/j.ajme.2017.01.005.

41. Rwegerwa GM. Adherence to anti-diabetic drugs among patients with type 2 diabetes mellitus at Mulhimbili national hospital, Dar es Salaam, Tanzania-A cross-sectional study. The Pan Afr Med J. 2014;17: 1–9.

42. Ganiyu AB, Mabuza LH, Malete NH, et al. Non-adherence to diet and exercise recommendations amongst patients with type 2 diabetes mellitus attending extension II clinic in Botswana. Afr J Primary Health Care and Family Med. 2013;5(1):1–6.

43. Parajuli J, Saleh F, Thapa N, et al. Factors associated with nonadherence to diet and physical activity among Nepalese type 2 diabetes patients: a cross sectional study. BMC Res notes. 2014;7(1):758–766. https://doi.org/10.1186/1756-0500-7-758

44. Feig DS, Hwee J, Shah BR, Booth GL, et al. Trends in incidence of diabetes in pregnancy and serious perinatal outcomes: a large, population-based study in Ontario, Canada, 1996–2010. Diabetes Care. 2014;37(6):1590–1596. https://doi.org/10.2337/dc13-2717

45. Evers IM, de Valk HW, Visser GHA. Risk of complications in pregnancy with women type 1 diabetes: nationwide prospective study in the Netherlands. BMJ. 2004;325:915–918. https://doi.org/10.1136/bmj.38043.583160.EE

46. HAPO Study Cooperative Research Group. Hyperglycemia and adverse pregnancy outcomes: the HAPO study cooperative research group. Obstetrical & Gynecological Surv. 2008;63(10):615–616.

47. Sopian IL, Saadiah Shahabudin MAA, Lung LTT, et al. Yeast infection and diabetes mellitus among pregnant mother in Malaysia. The Malaysian J Med Sci: MJMS. 2016;23(1):27–34.

48. Mathiesen ER, Hod M, Ivanisevic M, et al. Maternal efficacy and safety outcomes in a randomized, controlled trial comparing insulin detemir with NPH insulin in 310 pregnant women with type 1 diabetes. Diabetes Care. 2012;35(10):2012–2017.

49. Farrar D, Simmonds M, Sheldon T. Hyperglycaemia and risk of adverse perinatal outcomes: systematic review and meta-analysis. BMJ. 2016;354:i4694. https://doi.org/10.1136/bmj.i4694.

50. Alemu B, Olayinka O, Baydoun H, et al. Neonatal hypoglycaemia in diabetic mothers: a systematic review. Curr Pediatric Res. 2017;21(1):42–53.

Received: 27-11-2017 Accepted: 12-04-2018